CV Therapeutics (CVT) is a MF Rule Breakers pick, who has a nice write up on the company's great second quarter. They also estimate that the company is potentially seriously undervalued.
Zacks appears to agree, noting that a lot of the company's future success hinges on the company's pipeline.
No comments:
Post a Comment